SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Seattle Genetics (SGEN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Lokness who wrote (128)2/5/2009 6:56:18 PM
From: mcbio   of 161
 
That's a good question and one I'd like answered myself. I assume it's partly because of the partnership with DNA, including the terms of the partnership, and the fact that they're involved in next generation ADCs. And those things are certainly good but I'm not convinced they justify an $850 million dollar market cap.

I also would guess that part of the answer is in fact an inefficient market. The pricing of smaller biotechs in particular tends to be more inefficient.

I'm just saying I like a much higher risk/reward in my biotechs. When you're starting off at an $850 million dollar market cap, you better have a few big blockbusters actually make it to market if you want some serious price appreciation long-term.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News